Biotech Expo 生物展

The Shenzhen International Biotech and Health Industry Expo (Biotech) is hosted by the Shenzhen Municipal People’s Government and managed by Wen Global Solutions Inc.

Last year’s meeting represented products from 200 companies and about 80 innovative programs. It attracted more than 12,000 investors and professionals, and created huge business opportunities and values for the enterprises and companies in the biotech and health industry sector.

The biotech and health science sector has a tremendous and growing impact on people in modern society. It is key to higher quality of life and a doorway to improved health.

China’s health-care sector continues to develop at an astonishing rate: spending is projected to grow from $357 billion in 2011 to $1 trillion in 2020. From pharmaceuticals to medical products to consumer health, China remains among the world’s most attractive markets, and by far the fastest-growing of all the large emerging ones. It is not surprising that multinationals are flocking to take advantage of the opportunities, but long-term success is by no means assured. Although we remain optimistic about the overall outlook for China’s health-care market, multinationals will find it harder to compete. We expect a clearer separation between winners and laggards. Late entrants may struggle.

Three themes will shape China’s health-care market: the continuation of economic and demographic trends, further health-care reform, and the policies articulated in the government’s 12th five-year plan. Some of these forces—such as improvements in infrastructure, the broadening of insurance coverage, and significant support for innovation—will have positive implications for multinational companies. Others—for example, pressure on pricing and the rise of local champions—will have negative implications. In certain respects (including the bid to reconcile low-cost universal health-care coverage with rewards for innovation) the forces come into direct opposition. To paraphrase Vice Premier Li Keqiang, reform of the country’s healthcare system has entered ―uncharted waters.

The 2015 SIBHIE is scheduled for Sept 23 through Sept 25 at the Shenzhen Exhibition Center, coinciding with the 2015 Shenzhen International Biotech Leaders Summit (2015 SIBLS).  More...

        深圳国际生物/生命健康产业展览会每年一届在9月份举行。  展会集中展示了200多家企业产品,发布创新项目近80个,吸引行业投资者及专家观众12000人次,为生物生命健康领域企业创造了巨大的商机和价值。生物生命科学对当今世界人们的生活产生了深远的影响,成为人们对高质量生活追求的源头和打开健康之门。  

展会亮点:
1、展示交流:来自各国领军企业,为国内生物与生命健康行业带来国际先进的技术、设备及解决方案,通过展会的平台,促进和推动国内外生物及生命企业先进理念、管理和技术的交流与合作,成为加速生物与生命健康行业发展的助推器。

2、专业观众邀请包含:首席研究员,教授,企业高层,部门主管,实验室技术员,科研人员等,群体将覆盖亚洲、美洲及欧洲等,我们将会对国内外知名企业和机构发出邀请函,力争参展参会成员的构成体现跨国界、高层、多领域、专业性强等特点。

3、专业论坛:BT领袖峰会将邀请国内外产业领域知名领袖、杰出代表就生物技术与临床医疗等领域热点话题与政府、学者、企业等进行深入的交流和智慧的碰撞,共同探讨新形势下生物产业发展的最新进展和资本合作的共赢之道。

生物产业发展迎来变化  

          综合开发研究院公共经济与组织创新研究中心主任阮萌博士指出,目前,生命科学研究、生物技术发展不断取得重大突破。信息技术继续保持加速发展的态势,如云计算、超级计算、大数据等水平不断提升;基因检测、远程医疗费、个体化医疗等新业态和新的模式层出不穷。因此,生物产业将成为信息产业之后,世界经济的又一新主导产业。15年来,中国生物医药增长100倍。目前,生命健康领域的投资不断升温,不少IT公司、房地产公司都转向生命健康领域,如苹果刚刚发布了新产品iwatch,万通、新希望、万好国际等联合成立中国医疗健康产业发展策略联盟。详情

clip_image002